reason report
strong pharma nasd higher china
bottom line remain outperform price target
agil given well-diversifi posit across healthcar growth
end-market pharma dx genom lead posit
chem energi agil deliv strong quarter y/i org
growth vs street expect recal china gener
rev china food busi rev weigh heavili
last quarter investor expect mute head
despit continu drag china agil deliv strong quarter
growth pharma ex nasd strong contribut
nasd busi improv gc
seri sale genom patholog busi forens
driven steroid test also help quarter like
continu agil rais midpoint full year revenue guid
narrow rang continu expect strong growth pharma
off-set china weak help drive growth time core
instrument growth lsag remain flat
strong pharma nasd busi propel growth expect cell
therapi platform becom anoth key driver growth nasd
oligo rnai drug expect busi exit
year potenti doubl open
new facil furthermor recent announc acquisit
biotek ebitda appear compani
well way build strong portfolio cell therapi
expect creat busi annual revenu
expect biotek mesh well portfolio compani
agil compil last four year includ seahors
bioscienc luxcel bioscienc
effect build busi ground
rel low comp come next quarter expect continu
out-performance segment led primarili pharma
overhang china persist howev gener manufactur
demand improv small molecul busi recov rest
world two main overhang china market food
rule continu remain headwind line expect
rule headwind saw improv
instrument demand gener manufactur
first pilot grew encourag compani saw
sequenti improv gener manufactur howev
remain cautiou uncertainti head second pilot still
believ investor continu watch china close given agil
exposur rev agil expect new tariff impact minim
compani inform svb leerink llc research
revenu us million ep exclud item amort intang
price-to-earnings lt ep growth
life scienc tool diagnost
year price history/av daili volume mil
pleas refer page import disclosur price chart analyst certif
guid increas midpoint head final quarter
fiscal year agil increas midpoint fy revenu guid
slightli repres
core growth rate agil also increas
guid adj ep
compar prior revenu guidanc
 came slightli behind previou estim
guid adj ep compar prior remain
encourag beat quarter slight guidanc rais
fiscal year adjust estim accordingli
rate agil share outperform price target view agil
posit believ compani hold lead posit environment chemic
food test market around world maintain well-diversifi posit across
healthcar biopharma life scienc tool lst diagnost compani also repres
margin expans opportun medium long-term spin-off keysight
electron manag busi becom pure-play life scienc tool lst compani
agil continu deliv improv adjust oper margin despit growth initi
believ achiev exceed longer term leadership
ceo mcmullen agil compet aggress multipl market deliv solid growth
biopharma sale maintain either posit across
end-market includ food environment chemical/energi emerg market post
solid growth agil posit capit given sizabl exposur geographi
intuvo product cycl could repres opportun current under-
appreci agil repres compani develop core root industri
chemic electron market year transform life scienc tool
technolog leader diversifi access lead end-market
agil share current trade ev/ebitda under-valued compar
life scienc tool peer group averag
believ ev/ebitda valuat provid best measur agil valu
month price target expect agil trade line averag lst group
ev/ebitda multipl result appli ev/ebitda multipl
ebitda estim arriv pt
primari risk price target includ
biopharma declin pose greatest risk agil margin expans plan declin
biopharma fund could highli impact agil revenu given revenu lever
biopharma industri believ gener biopharma price risk mute given
elect outcom howev impact regulatori chang could see
biopharma compani becom cautiou spend could impact capit
equip purchas includ agil slowdown biopharma fund would
result downsid risk estim valuat biomolecul forecast ramp
drug market mid-teen believ prolifer drive
use agil mass spectromet character molecul pronounc
slowdown biopharma core growth requir margin expans would
slowdown global budget research could pose downsid risk forecast tighten
budget govern academ fund could result lower revenu rel
estim agil much academ government exposur
competitor nevertheless slowdown academ spend could
headwind plan margin expans assum expect core growth furthermor
restrict global budget could result shift focu strategi growth could
increas oper risk declin government spend could risk downsid
forecast growth nih spend flat low-single-digit
soft demand emerg market could derail growth forecast geopolit risk emerg
market could disrupt oper downsid risk valuat forecast geopolit
risk could also impact agil strategi creat higher barrier entri exist futur
market agil oper numer intern market includ china middl east
europ macroeconom impact chines market could lead declin compani
revenu regul chines polici could also caus restrict oper lead
lower activ china question remain china concern detail
headwind could emerg polici risk
continu volatil energi chemic sector could impact growth agil
consider exposur revenu chemic energi industri agil expect
recoveri next year continu volatil crude oil could result downsid risk
agil expect low-single-digit growth next year volatil oil price could impact
budget next year spend certain countri dictat commod price
would lead lower spend chemic energi
dollar million except per share data
good sold
sg sale
 sale
oper expens sale
compani report svb leerink estim
